Orphazyme's hour of reckoning approaches: "Its existence is threatened if it gets a clear no"

The US FDA will present its verdict on Orphazyme's drug candidate arimoclomol for treating NPC on June 17 at latest. According to an analyst and a former investor, the outcome is crucial to the Danish biotech firm.
Photo: Orphazyme/PR
Photo: Orphazyme/PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN AND CATHERINE BRETT

Orphazyme's fate as a biotech company may be at stake when the US Food and Drug Administration (FDA) decides whether arimoclomol can be approved as a treatment for the rare metabolic disorder Niemann-Pick type C (NPC), says Danske Market's Senior Analyst Thomas Bowers.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading